Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study
Current Oncology · 2024
DOI: 10.3390/curroncol31070287 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Current Oncology, 2024. Verfasst von Gwynivere A Davies und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hamilton Health Sciences, Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Canada. Hauptthemen laut MEDLINE: Hodgkin Disease, Brentuximab Vedotin, Immunoconjugates. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cost-effectiveness analyses are required for therapies within Canada’s universal healthcare system, leading to delays relative to U.S. healthcare. Patients with Hodgkin lymphoma (HL) generally have an excellent prognosis, but those who relapse after or are ineligible for transplant benefit from novel therapies, including brentuximab vedotin (BV). BV was FDA-approved in 2011 but not Canadian-funded until 2014. To assess the impact of access delays, we compared changes in survival for U.S. (by insurer) and Canadian patients in periods pre/post-U.S. approval. Patients were 16–64 years, diagnosed with HL in 2007–2010 (Period 1) and 2011–2014 (Period 2) from the U.S. SEER and Canadian Cancer Registries. Approval date (surrogate) was utilized as therapy was unavailable in registries. Kaplan-Meier survival curves and adjusted Cox regression models compared survival between periods by insurance category. Among 12,003 U.S. and 4210 Canadian patients, survival was better in U.S. patients (adjusted hazard ratio (aHR) 0.87 (95%CI 0.77–0.98)) between periods; improvement in Canadian patients (aHR 0.84 (95%CI 0.69–1.03) was similar but non-significant. Comparisons between insurers showed survival was significantly worse for U.S. uninsured and Medicaid vs. U.S. privately insured and Canadian patients. Given the increasingly complex nature of oncologic funding, this merits further investigation to ensure equity in access to therapy developments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hamilton Health Sciences, Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Canada.
- Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
ORCID-Profile: Kristen D Brantley
Zitieren
APA
Davies, G. A., Orav, J. E., & Brantley, K. D. (2024). Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study. Current Oncology. https://doi.org/10.3390/curroncol31070287
Vancouver
Davies GA, Orav JE, Brantley KD. Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study. Current Oncology. 2024. doi:10.3390/curroncol31070287
BibTeX
@article{Davies2024,
author = {Davies, Gwynivere A and Orav, John E and Brantley, Kristen D},
title = {Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31070287}
}
EUVIMED